Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $523.93 -2.1%
Revenue Growth %: +10.7%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +10.7%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex's povetacicept hits key endpoints in Phase 3 kidney disease trial
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
